First Clinical Trial in MOGAD Meets Primary Endpoint

(MedPage Today) -- The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Satralizumab reduced the risk of...
Source
MedPage Today
Opens original article in a new tab



